Matches in Wikidata for { <http://www.wikidata.org/entity/Q64150295> ?p ?o ?g. }
Showing items 1 to 48 of
48
with 100 items per page.
- Q64150295 description "clinical trial" @default.
- Q64150295 description "ensayu clínicu" @default.
- Q64150295 description "klinisch onderzoek" @default.
- Q64150295 description "клінічне випробування" @default.
- Q64150295 name "Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)" @default.
- Q64150295 type Item @default.
- Q64150295 label "Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)" @default.
- Q64150295 prefLabel "Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)" @default.
- Q64150295 P1132 Q64150295-63DAD920-EEB5-4AEB-918B-AE112437516D @default.
- Q64150295 P1476 Q64150295-88EA0C50-2F8B-4B8A-A71C-3BEBF74658D7 @default.
- Q64150295 P17 Q64150295-0A37A224-B0B7-45CC-875A-A912790F12B1 @default.
- Q64150295 P17 Q64150295-3495B59A-9C3E-41B3-B676-07B132BB0E46 @default.
- Q64150295 P17 Q64150295-94D7B27B-DC14-4B05-A14C-81E90153EE7A @default.
- Q64150295 P17 Q64150295-987AC157-C099-4677-BC42-C40C854BD86E @default.
- Q64150295 P17 Q64150295-C4CC8B3B-CB94-4942-A965-9D4AF67C7F4A @default.
- Q64150295 P17 Q64150295-CDD90D0C-7EC5-4C85-B75B-33C2BFDA22FF @default.
- Q64150295 P17 Q64150295-D2FE3810-2E8B-4900-B080-15BC1D1A3407 @default.
- Q64150295 P2899 Q64150295-6611DF49-79D7-41A0-951E-ECD2B5B74E80 @default.
- Q64150295 P3098 Q64150295-178945B9-EC1B-4D48-866E-E047E3128525 @default.
- Q64150295 P31 Q64150295-8C3453C0-CD1D-4B9E-AB07-B713BDE0A4E7 @default.
- Q64150295 P4844 Q64150295-72B5EDF3-2828-418B-8643-95161AC6D97C @default.
- Q64150295 P4844 Q64150295-96E9FB39-4442-4B7C-BC96-44EA1CE35AD0 @default.
- Q64150295 P4844 Q64150295-BA231D22-150F-44A3-9C70-B65EFAA870DE @default.
- Q64150295 P580 Q64150295-E9E95E7B-4ABC-44BF-ABBD-8FD6A01ED520 @default.
- Q64150295 P582 Q64150295-E78A7B73-8C6F-4FAB-8EBE-3786369D4CE0 @default.
- Q64150295 P6099 Q64150295-E1BAE08C-33B3-4411-B1D9-9A486048A594 @default.
- Q64150295 P6153 Q64150295-864C68F5-E2D6-4A7D-928C-72240007318B @default.
- Q64150295 P8363 Q64150295-4D770C5B-765D-4F17-B9D2-12F2A6BEBD62 @default.
- Q64150295 P1132 "+1000" @default.
- Q64150295 P1476 "A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone Versus Placebo Plus Docetaxel Plus Prednisone in Participants With Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)" @default.
- Q64150295 P17 Q142 @default.
- Q64150295 P17 Q29 @default.
- Q64150295 P17 Q30 @default.
- Q64150295 P17 Q38 @default.
- Q64150295 P17 Q408 @default.
- Q64150295 P17 Q801 @default.
- Q64150295 P17 Q865 @default.
- Q64150295 P2899 "+18" @default.
- Q64150295 P3098 "NCT03834506" @default.
- Q64150295 P31 Q30612 @default.
- Q64150295 P4844 Q13896859 @default.
- Q64150295 P4844 Q408524 @default.
- Q64150295 P4844 Q424972 @default.
- Q64150295 P580 "2019-05-02T00:00:00Z" @default.
- Q64150295 P582 "2021-09-12T00:00:00Z" @default.
- Q64150295 P6099 Q42824827 @default.
- Q64150295 P6153 Q96149477 @default.
- Q64150295 P8363 Q78089383 @default.